Grant: Engage Grants Program
University of Guelph
$25,000.00
Pre-clinical evaluation of combined CBDA:THCA on nausea in veterinary medicine
EF 2018-19
Résumé
Cannabis has been used to treat nausea and vomiting for thousands of years. Indeed, this symptom was the first to receive approval for medical marijuana prescriptions. The primary psychoactive ingredient in cannabis is tetrahydrocannabidiol (THC) and another non-psychotropic ingredient in cannabis is cannabidiol (CBD) which both have anti-nausea and anti-emetic properties. However, recently, our group has shown that the acidic precursors to THC, THC-acid (THCA), and to CBD, CBD-acid (CBDA), are much more potent anti-nausea agents then their products after heating. Indeed, THCA is non-psychotropic and may be a better treatment than its psychotropic product. Indeed, CBDA is 1000 times more potent in reducing nausea and vomiting than CBD, but has no psychomotor effects. Since CBDA and THCA are both present (at various concentrations depending upon strain) in the raw cannabis plant, the present research will determine the potential synergistic effects of these compounds, one that acts on 5-HT1A receptors (CBDA) and the other which acts on CB1 receptors (THCA possibly peripherally) to reduce nausea and vomiting for potential development as veterinary medicines. There has been very little research on the effects of combinations of these compounds on nausea and vomiting. Here we propose to evaluate the potential of various combinations of THCA:CBDA doses to more effectively reduce nausea than either agent on its own. We will also determine if the effects of THCA on nausea are peripherally or centrally mediated. The results of these experiments will provide pre-clinical evaluation of potential new therapies for companion animals undergoing chemotherapy treatment.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
531553-2018
Name nom
Parker, Linda
Department département
Psychology
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
505
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Veterinary pharmaceuticals
Area of application fr
Produits pharmaceutiques à usage vétérinaire
Research subject code
6308
Research subject group en
Psychology
Research subject group fr
Psychologie
Research subject en
Behavioural neuroscience
Research subject fr
Neurologie du comportement
Partie
1
Nb partie
1
Application title
Pre-clinical evaluation of combined CBDA:THCA on nausea in veterinary medicine
Keyword
NSERC
Application summary
Cannabis has been used to treat nausea and vomiting for thousands of years. Indeed, this symptom was the first to receive approval for medical marijuana prescriptions. The primary psychoactive ingredient in cannabis is tetrahydrocannabidiol (THC) and another non-psychotropic ingredient in cannabis is cannabidiol (CBD) which both have anti-nausea and anti-emetic properties. However, recently, our group has shown that the acidic precursors to THC, THC-acid (THCA), and to CBD, CBD-acid (CBDA), are much more potent anti-nausea agents then their products after heating. Indeed, THCA is non-psychotropic and may be a better treatment than its psychotropic product. Indeed, CBDA is 1000 times more potent in reducing nausea and vomiting than CBD, but has no psychomotor effects. Since CBDA and THCA are both present (at various concentrations depending upon strain) in the raw cannabis plant, the present research will determine the potential synergistic effects of these compounds, one that acts on 5-HT1A receptors (CBDA) and the other which acts on CB1 receptors (THCA possibly peripherally) to reduce nausea and vomiting for potential development as veterinary medicines. There has been very little research on the effects of combinations of these compounds on nausea and vomiting. Here we propose to evaluate the potential of various combinations of THCA:CBDA doses to more effectively reduce nausea than either agent on its own. We will also determine if the effects of THCA on nausea are peripherally or centrally mediated. The results of these experiments will provide pre-clinical evaluation of potential new therapies for companion animals undergoing chemotherapy treatment.